The herpes simplex virus 1 (HSV-1) tegument protein VP22 has been utilised as a vehicle for trafficking proteins. It has a remarkable property of exiting the cell that is producing it and entering the neighbouring cells, which has been used to deliver therapeutic proteins, p53 and herpes simplex virus thymidine kinase (tk). It has a complex pattern of expression and subcellular localisation. Functions of VP22 include intercellular transport, binding to and bundling of microfilaments, inducing cytoskeleton collapse, nuclear translocation during mitosis, and binding to chromatin and nuclear membrane. The regions of VP22 which contain each of these functions have not been characterised. Finding the region carrying the
Introduction
The herpes simplex virus-1 protein VP22 is a major component of the herpesvirus tegument, the region between the envelope and capsid of the virus particle. It has a complex pattern of expression and subcellular localisation. In expressing cells, VP22 is first localised in the cytoplasm, where it binds to microtubules and induces collapse of the cytoskeleton creating a large perinuclear lump. After the nuclear membrane has disintegrated in early mitosis, VP22 translocates into the nucleus and binds to chromatin, where it remains until after completion of mitosis and during the next interphase. 1 The determinants of microtubule binding and reorganisation, nuclear translocation, and chromatin binding have not been elucidated. In addition to its functions in the expressing cells, VP22 has the capability of intercellular spread, whereby the protein exits producing cells and enters neighbouring cells, where it translocates into the nucleus. 2 This property is maintained in protein fusions with VP22, which can be utilised to transfer potentially therapeutic proteins into target cells.
It has been recently demonstrated that VP22 can deliver the tumour suppressor protein p53 from expressing cells to neighbouring recipient cells where p53 retained its function in inducing cell cycle arrest and apoptosis. 3 We have previously constructed a fusion gene encoding VP22-tk, ie VP22 fused to herpes simplex virus thymidine kinase (tk), in retroviral backbones. This protein was found to retain the intercellular trafficking properties of VP22, as well as tk enzyme activity. The VP22-tk protein spreads between cells in sufficient quantities to induce cell death in response to ganciclovir (GCV) treatment not only in the primary synthesising (a.k.a. synthetic) cells but also in surrounding recipient cells, thus causing a bystander phenomenon even in cells devoid of gap junctions. This effect was observed upon GCV treatment of transfected tissue culture cells and in vivo in mice injected with tumour cells transduced with VP22-tk fusion genes. 4 However, the effect was only observable with a relatively high percentage (50%) of VP22-tk-synthesising cells as compared with non-VP22-tk expressing cells in the tumour cell mixture.
The green fluorescent protein (GFP) is detectable in individual cells without the use of exogenous agents, such as enzyme substrates. The localisation of GFP is essentially nonrestricted; that is, it is freely distributed in the cell cytoplasm as well as the nucleus. This makes GFP a useful reporter for studies of protein localisation. In previous studies it has been shown that a GFP-VP22 fusion protein retains the properties of the native VP22 in a recombinant HSV-1 virus, 5 and allowed the characterisation in detail of the subcellular localisation of VP22 1 and its intercellular transfer. [6] [7] [8] [9] GFP-VP22 fusion protein has been found to retain the intercellular trafficking properties of VP22 in all the cell lines studied.
We theorised that the different functions of VP22 may 
Results
The deletion constructs were made as fusions to EGFP and EYFP and are depicted in Figure 1a . The plasmids were transfected into Cos-7 cells and the cells were analysed 24 and 48 h later. To confirm the identity of the constructs, Western blotting of the transfected cell lysates was performed using antibodies to the HA tag (data not shown) and GFP ( Figure 1b) . Localisation of the GFPtagged constructs in live and fixed cells was assessed by fluorescence microscopy. The localisation pattern in PFAfixed cells was found to be identical in living cells. Cells were studied fixed to maintain their morphology at room temperature.
Subcellular localisation of GFP-VP22 deletion constructs in living cells
To characterise the localisation and function of VP22 fragments, we transfected Cos-7 cells with the VP22 deletion constructs fused to GFP. We observed the cells at 24 and 48 h after transfection ( Figure 2 ). In line with the results published by us and others, 2,6 the localisation of fulllength GFP-VP22 was filamentous in the early stages of transfection, ie up to about 36 h, followed by change to a bright perinuclear body and nuclear translocation of the fluorescent protein at 48 h after transfection. As a control, localisation of GFP was compared with the localisation of the constructs. GFP showed diffuse nuclear and cytoplasmic localisation at all times. The deletion constructs had each a distinct localisation pattern, and these are described below.
⌬C121 localisation was diffuse, predominantly nuclear with slight nucleolar concentration at all times. After methanol fixation ⌬C121 was not retained well inside the cells, so some loss of signal could be observed. However, near complete loss of fluorescence is observed with GFP.
⌬N81 closely resembles full-length VP22 in its subcellular localisation and retains the intercellular trafficking capability. The properties of microtubule binding, cytoskeleton collapse, nuclear localisation and chromatin binding are all retained by this N-terminally deleted VP22. Before cell division, ⌬N81 binds to the cytoskeleton and induces cytoskeleton collapse. During mitosis, ⌬N81 binds to chromosomes (inset in Figure 2 ), but remains diffusely detectable in the cytoplasm as well. After cell division it remains in the cell nucleus, but also remains easily detectable in the cytoplasm. The capability to induce cytoskeleton collapse is diminished in ⌬N81 compared with wt GFP-VP22. Fifty per cent of expressing cells show bundled cytoskeleton at 48 h after transfection even after cell division. In producer cells localisation does not change after fixation by PFA or methanol.
⌬N119 binds to cytoskeleton and induces its collapse at 24 h after transfection when it is not localised in the cell nucleus. At 48 h, however, when the cytoskeleton has collapsed, ⌬N119 can be found as a perinuclear lump and distinct speckles on the nuclear membrane, but not inside the nucleus.
F81-195 localises diffusely in the cell cytoplasm and nucleus, with more pronounced nuclear-nucleolar predominance when the expression level is low. The localisation does not change after cell division.
F119-195 localises diffusely in the cytoplasm and nucleus when the expression level is low at 24 h. Cells expressing more protein show a collapsed cytoskeleton. At 48 h all cells show a collapsed cytoskeleton and an 'empty', nonfluorescent nucleus.
F159-195 remains in the cytoplasm before and after cell division. It localises as a 'foamy' network. No cytoskeleton collapse was observed.
⌬N195 was found in the cytoplasm. At 24 h already 90% of the ⌬N195 expressing cells had a collapsed cytoskeleton, a markedly rounded shape and a strongly fluorescent perinuclear aggregate. Methanol fixation did not change this localisation.
⌬N267 localised diffusely in the cell cytoplasm and nucleus, with more pronounced nuclear-nucleolar predominance when expression levels were low. Localisation did not change after cell division. After methanol fixation cytoplasmic localisation of the fluorescent protein became more predominant due to a considerable loss of nuclear signal. No fluorescence was detectable in the surrounding cells after methanol fixation. Figure 3 shows the transport capacity of the two deletion constructs which still allowed intercellular trafficking (⌬N81 and F81-195). Other constructs were not detectable in surrounding cells after methanol fixation (data not shown). While full-length GFP-VP22 localises primarily in the recipient cell nucleus and only a minor fraction can be found in the cytoplasm, construct ⌬N81 was localised predominantly in the recipient cell cytoplasm as filamentous structures. The recipient cells nuclei were characterised by lack of fluorescence. F81-195 could be found diffusely throughout the cell, with a slight concentration in the nucleus. The ease of detection of F81-195 in non-producer cells is considerably diminished compared with full-length GFP-VP22 and ⌬N81 (compare the signal in Gene Therapy surrounding cells on Figure 3) . However, the amount of F81-195 in surrounding cells may be underestimated due to its diminished capacity to bind the cytoskeleton and to chromatin, resulting in a more diffuse signal. Panels a and b depict the same fields. In panel a, only GFP fluorescence is shown, in panels b and c blue colour identifies cell nuclei. In panel c, the fusion proteins are detected by GFP antibody, followed by Cy-3-conjugated secondary antibody (red). The transfected, ie synthetic cells appear yellow due to the balance of green and red signals. Note the excess of red signal in the surrounding cells, indicating partial loss of GFP function upon transportation.
Intercellular spread
The properties of each of the constructs are summarised in Table 1 .
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Figure 3 Intercellular spread of GFP-VP22 deletion constructs. Only the constructs showing detectable cell to cell spread are shown. Transfected Cos-7 cells were fixed with methanol and photographed 48 h after transfection. Original magnification ×40. (a) GFP fluorescence; (b) the same field: GFP (green), cell nuclei stained with bisbenzimide (blue); (c) GFP (green), cell nuclei (blue) and GFP detected by Cy-3 (red).

Table 1 Properties of the VP22 deletion constructs
Cytoskeleton Nuclear and Binding to Chromatin Intercellular binding and nucleolar nuclear binding transport reorganisation localisation membrane
The exact mechanism of VP22 function is not known. It is likely that various dynamic interactions of VP22 with different cellular proteins are required. The functional properties of VP22 can be broadly divided into nuclear localisation, nucleolar localisation, chromatin binding, microtubule binding, induction of cytoskeleton collapse and intercellular transport. We theorised that these functions may be separable in the VP22 polypeptide. Therefore, we constructed a series of deletion mutants as fusions to N-and C-terminus of EGFP protein. EGFP does not affect VP22 functions and has been used by us 6 and others 5 to tag VP22. All the deletion constructs retained some of the specific functions of VP22. As a result, we could identify the regions of VP22 required for cytoskeleton binding and reorganisation, nuclear and nucleolar localisation, nuclear membrane localisation and intercellular transport. These regions are depicted in Figure 4 .
We mapped the amino acids critical for binding to and reorganising cytoskeleton to between positions 159 and 267 (Figure 4a ). Amino acids 159-195 (construct F159-195) localise in a network-like structure, but do not induce collapse. In F119-195, however, destabilisation of the cytoskeleton is more prominent, but only in cells with higher levels of F119-195 expression. ⌬N195 induced a strong cytoskeleton collapse even at early times of expression. Because of the marked difference in cytoskeleton collapsing activity between the constructs ⌬N81 and ⌬N119, and between F81-195 and F119-195, we conclude that amino acids 81-119 contain elements inhibitory to cytoskeleton collapse (compare constructs F81-195 and F119-195 at 48 h).
⌬C121, ⌬N267 and F119-195 localised to the cell nucleus independent of the cell cycle stage; mitosis was not necessary for the nuclear translocation of these constructs. No association was seen with mitotic chromatin. ⌬N267 and F119-195 were concentrated in the nucleoli. ⌬C121 was concentrated in the nucleoli by 24 h; later the higher level of expression resulted in a general diffuse localisation of the protein. This suggests that there are at least two separate determinants of nuclear and nucleolar localisation in the VP22 protein. These are the regions between 81-121 and 267-301 (Figure 4b ). All these three constructs are of a sufficiently small size (⌬C121 = 40.6 kDa, ⌬N267 = 33.2 kDa and F81-195 = 42.0 kDa) to be able to diffuse into the nucleus in the absence of a specific transport signal. However, retention in the nucleus and nucleoli, most probably results from a specific interaction. Binding to chromatin was maintained only in the N-terminally deleted ⌬N81. Construct ⌬N119 displayed a speckled pattern at the nuclear membrane, but did not bind to chromosomes or interphase chromatin. This suggests that binding to chromatin is a co-operative function, which requires several regions in the VP22 peptide 81-301, and aa 81-119 are necessary, but not sufficient, for the function (Figure 4c) .
Nuclear membrane localisation displayed by ⌬N119 is also a co-operative function within the peptide 119-301, and which requires the presence of aa 119-159.
The construct ⌬C267 has been previously reported not to spread between cells, 2 suggesting that the C-terminus is necessary for intercellular transport. In agreement with these previous results, ⌬N81 could spread, but a different localisation pattern was observed in recipient cells. Surprisingly, the construct F81-195, which lacks both the Nand C-terminal portion, showed a reduced, but detectable intercellular spread. Therefore, we conclude that the N-terminal 80 amino acids do not contribute to intercellular spread of VP22. Instead, the N-terminal may contain a negative regulatory function which is counteracted by the C-terminal portion of VP22. The constructs ⌬N195 and ⌬C121 are not detectable in surrounding cells after methanol fixation. Based on this, we mapped the property to spread between cells, which can be detected visually after methanol fixation, to amino acid positions 81-195 (Figure 4e) . We propose a model for VP22 function, where each functional region either binds to a cellular partner to facilitate its function, or to another region within the VP22 protein, in which case these functions are blocked.
As a protein capable of intercellular transport, VP22 has been shown to be a potentially useful component in bystander cell targeting in gene therapy. The capacity of the fragments of VP22 described here to induce bystander cell death, in the absence of gap junctions, in HSV-TK -GCV suicide gene therapy model is currently under investigation, although it seems likely that none of the identified fragments will be as effective in inducing bystander cell death as the full-length VP22 protein.
We have dissected the functional domains of VP22 by Cells were seeded at 50-60% confluency the previous day and transfected with plasmids by Fugene 6 reagent (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. Briefly, DNA (0.2-1.0 g) and Fugene 6 reagent were mixed in 100 l serum-free cell culture medium at the mass:volume ratio 1:2 and added to cells after 15 min.
The cells were fixed 24 or 48 h after transfection with 100% methanol, or 3% paraformaldehyde (PFA) at room temperature for 15 min.
Plasmids pEGFP-VP22 was created by cloning into the BamHI site of pEGFP-C1 (Clontech, Palo Alto, CA, USA) a BglIIBamHI fragment from pUL49epB 7 and adding the BamHI-XbaI fragment from pINSHNES (both kind gifts from Dr P O'Hare, Marie Curie Research Institute, Oxted, UK) containing the hemaglutinin (HA) epitope. Deletion constructs fused to EGFP were created by the following strategy: pEGFP-VP22 was cleaved with ApaI and XbaI. The 5′ fragment of the VP22 gene (ApaI-ApaI) was cloned in frame to pEYFP-N1 (enchanced yellow fluorescent protein -a spectral variant of GFP) yielding the construct ⌬C121. The ApaI-XbaI fragment was cloned in frame into pEGFP-C3 to yield the construct ⌬N119. This in turn was cleaved with SmaI-XbaI and the resulting fragment was cloned into pEGFP-C3 to yield the construct ⌬N195. To make the construct F119-194, plasmid ⌬N119 was cleaved with NaeI and BamHI, the ends flushed with Klenow enzyme and religated. To make ⌬N81, pUL49epB was cleaved with PpuMI and the ends filled with Klenow enzyme. Then it was cut with XbaI and cloned into pEGFP-C2. F81-195 was made by cleaving ⌬N81 with NaeI and BamHI, filling the ends with Klenow and religation. To make F159-195, the SalI-SalI fragment from F119-195 was cloned into SalI site of pEGFP-C3. The SalIXbaI fragment from ⌬N195 was cloned into pEGFP-C1 to make ⌬N267. All constructs were sequenced at GFP-VP22 junctions to confirm their identity.
Western blotting
Transfected 293 cell lysates were separated on a 10% SDS-PAA gel, blotted on to a nitrocellulose filter and detected with anti-GFP antibody (Clontech) followed by HRP con-jugated goat anti-rabbit antibody. Blots were detected with SuperSignal ULTRA chemiluminescence detection kit from Pierce (Rockford, IL, USA).
Immunodetection
For immunodetection, anti-GFP rabbit polyclonal antibody was used (Clontech) and secondary donkey-antirabbit Cy-3 conjugate antibody (Jackson Immunoresearch Laboratories, West Grove, PA, USA) both according to manufacturer's instructions. The cells were washed once in PBS, blocked for 2 h with BSA and incubated with the primary antibody in blocking solution overnight at dilution suggested by the manufacturer, at room temperature, followed by four washes with PBS. The secondary antibody was diluted in the blocking solution and incubated for 1 h at room temperature, followed by four washes with PBS. Hoechst stain (Bisbenzimide H33342; Fluka Biochemica, Buchs, Switzerland) was used to counterstain the nuclei, at 1:4000 dilution in PBS, for 5 min at room temperature followed by one PBS wash.
Microscopy
Photographs were taken at 24-48 h after transfection with a Leica DM RXA confocal microscope (Leica Microsystems, Heidelberg Germany) and a Spectra Source Orbis digital camera (SpectraSource Instruments, Westlake Village, CA, USA). Image processing was done using Slidebook 2.1.5 (Intelligent Imaging Innovations, Denver, CO, USA) and Adobe PhotoShop 5.0 (Adobe Systems, Seattle, WA, USA).
